Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Robertson Stephens Wealth Management LLC

Robertson Stephens Wealth Management LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 32.4% in the 4th quarter, Holdings Channel reports. The firm owned 5,349 shares of the biopharmaceutical company’s stock after buying an additional 1,310 shares during the period. Robertson Stephens Wealth Management LLC’s holdings in Gilead Sciences were worth $433,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Nilsine Partners LLC lifted its stake in Gilead Sciences by 1.1% during the third quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock valued at $891,000 after buying an additional 127 shares in the last quarter. Etesian Wealth Advisors Inc. raised its position in Gilead Sciences by 0.7% during the fourth quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after buying an additional 128 shares during the period. Financial Counselors Inc. increased its holdings in shares of Gilead Sciences by 1.5% in the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock valued at $718,000 after purchasing an additional 128 shares during the period. Revolve Wealth Partners LLC lifted its position in shares of Gilead Sciences by 3.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 130 shares in the last quarter. Finally, Institutional & Family Asset Management LLC boosted its holdings in shares of Gilead Sciences by 10.3% during the third quarter. Institutional & Family Asset Management LLC now owns 1,501 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 140 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares in the company, valued at approximately $7,026,339.84. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Performance

Shares of GILD opened at $64.78 on Friday. The company has a market capitalization of $80.66 billion, a PE ratio of 179.94, a price-to-earnings-growth ratio of 1.31 and a beta of 0.22. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.98 and a quick ratio of 0.72. Gilead Sciences, Inc. has a one year low of $64.33 and a one year high of $87.86. The company’s fifty day moving average price is $70.72 and its 200 day moving average price is $75.94.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. During the same period in the previous year, the company posted $1.37 earnings per share. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. As a group, analysts expect that Gilead Sciences, Inc. will post 3.74 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be given a $0.77 dividend. The ex-dividend date is Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.75%. Gilead Sciences’s dividend payout ratio is 855.56%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on GILD. Barclays dropped their price target on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a research note on Monday, April 29th. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 27th. Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and reduced their price target for the company from $91.00 to $82.00 in a report on Thursday, February 22nd. Maxim Group dropped their price objective on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Cantor Fitzgerald reduced their target price on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research note on Wednesday, February 7th. Eleven analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $83.69.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.